中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (7): 526-529.doi: 10.12144/zgmfskin202607526

• 病例报告 • 上一篇    下一篇

弥漫性大B细胞淋巴瘤继发皮肤损害一例

马瑜1,杨家慧2,董灵娣2,安新月1,扈容英2,夏莉2,喻楠2   

  1. 1宁夏医科大学第一临床医学院，宁夏银川，750004；2宁夏医科大学总医院，宁夏银川，750003
  • 出版日期:2026-07-15 发布日期:2026-06-29

Diffuse large B-cell lymphoma with secondary cutaneous lesions: a case report

MA Yu1, YANG Jiahui2, DONG Lingdi2, AN Xinyue1, HU Rongying2, XIA Li2, YU Nan2   

  1. 1 First Clinical College of Ningxia Medical University, Yinchuan 750004, China; 2 General Hospital of Ningxia Medical University, Yinchuan 750003, China
  • Online:2026-07-15 Published:2026-06-29

PDF (PC)

19

摘要： 弥漫性大B细胞淋巴瘤（diffuse large B-cell lymphoma, DLBCL）是最常见的侵袭性非霍奇金淋巴瘤，可累及皮肤等多种结外器官。本文报道一例初诊为胃部DLBCL（生发中心型）的60岁男性患者，经R-CHOP方案化疗达完全缓解后，很快出现皮肤肿物，病理及免疫组化显示转化为非生发中心型，且Ki-67增殖指数高达85%。调整为Pola-BR方案（维泊妥珠单抗联合苯达莫司汀及利妥昔单抗）治疗后，皮肤肿物在第1周期化疗后即迅速消退。

关键词: 弥漫性大B细胞淋巴瘤, 皮肤受累, Pola-BR

Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, capable of involving multiple extranodal organs including the skin. This report describes a 60-year-old male patient initially diagnosed with gastric DLBCL (germinal center type). After achieving complete response (CR) with R-CHOP chemotherapy, he rapidly developed cutaneous masses. Pathology and immunohistochemistry revealed transformation to a non-germinal center subtype with a Ki-67 proliferation index as high as 85%. Following treatment adjustment to the Pola-BR regimen (Polatuzumab vedotin combined with Bendamustine and Rituximab), the skin lesions rapidly regressed after the first cycle of chemotherapy.

Key words: diffuse large B-cell lymphoma, skin involvement, Pola-BR